Premium
Clinical Trial with Clofazimine for Treating Erythema Dyschromicum Perstans Evaluation of Cell‐Mediated Immunity
Author(s) -
PiqueroMartían Jaime,
PéarezAlfonzo Ricardo,
Abrusci Vito,
Briceno Luis,
Gross Ana,
Mosca Walter,
Tapia Felix,
Convit Jacinto
Publication year - 1989
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1989.tb02466.x
Subject(s) - clofazimine , medicine , lymphoproliferative response , concanavalin a , immunology , cellular immunity , t cell , erythema , leprosy , immune system , dermatology , pharmacology , in vitro , biology , peripheral blood mononuclear cell , biochemistry
Eight patients were studied to determine the possible use of clofazimine for treating erythema dyschromicum perstans (EDP). The T‐helper/T‐suppressor cytotoxic ratio (CD‐4/CD‐8) and the in vitro lymphoproliferative response on stimulation with phytohemaglutin (PHA) and concanavalin A (Con A) were determined in peripheral blood before and after treatment. Of the eight patients studied, seven had excellent to good responses, whereas only one had a marginal response. The immunologic evaluation before and after treatment showed a significant change in the CD‐4/CD‐8 ratio, a decrease of the response to PHA, and no change in the response to Con A. The results obtained show that clofazimine is useful for treating this nosologic entity because of its cosmetic effect, and also because it induces changes in cell‐mediated response, which could be very important therapeutically.